Dexosome cancer immunotherapy (Institute Gustave-Roussy)
N/A
Report date: 2022/01/14 13:23:58
Base Information
Drug NameDexosome cancer immunotherapy (Institute Gustave-Roussy)
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesInstitute Gustave-Roussy
China Registration ClassN/A
Develop Information
Active CompaniesN/A
Inactive CompaniesDuke University Medical CenterInstitute Gustave-Roussy
Active IndicationsN/A
Inactive Indications
Other Information
ATC CodeN/A
Related LinksN/A